Trial Profile
To describe the frequency and nature of Lanreotide and Octreotide dose escalations in patients with advanced Gastroenteropancreatic neuroendocrine tumors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 May 2017
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary) ; Octreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 26 May 2017 New trial record
- 24 May 2017 Results presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research